

President's Emergency Plan for AIDS Relief (PEPFAR) "The Basics"

Tina T. Nhu

Commander, U.S. Public Health Service Team Leader Regulatory Project Manager, Division of Project Management Office of Generic Drugs |CDER | U.S. FDA

Regulatory Best Practices for Global Access to Medicines, Including Anti-TB Medicines August 17, 2022

Overview

FDA

- PEPFAR program and its impact
- The roles of Generic Drugs in PEPFAR
- FDA's Tentative Approval Process (TA) for the Abbreviated New Drug Application (ANDA)
- PEPFAR eligibility and its criteria
- PEPFAR Change Amendments
- Practice Pearls





THE IMPORTANCE OF THE PEPFAR PROGRAM AND ITS OVERVIEW

What is PEPFAR?



President's Emergency Plan for AIDS Relief

Initiative to address global HIV/AIDS epidemic

To date, PEPFAR funding has totaled more than \$110 billion To date, 239 PEPFAR Applications with 303 products

13 Priority Countries




Priority High Burden Countries


U.S. President's Emergency Plan for AIDS Relief (PEPFAR) Countries

Haiti	Zambia
United Republic of Tanzania	Uganda
Zimbabwe	Malawi
Lesotho	Cote d'Ivoire
Botswana	Namibia
Swaziland	Kenya
Rwanda	


www.fda.gov



PEPFAR Program Goals



FDA



www.fda.gov

Generic Drugs

Safe and effective



Commonly Encountered



Affordable


Global Savings

Role of Generic Drugs in PEPFAR



Review and Tentatively Approve antiretroviral (ARV) ANDAs for procurement under PEPFAR

Protects domestic patents of the Reference Listed Drug (RLD) Saves \$ for the PEPFAR program, while ensuring the medications purchased are safe and effective



www.fda.gov

505(j) ANDA Pathway

FDA

Generic drug applicants do not repeat clinical or preclinical studies to establish safety or efficacy. ANDAs can be approved if they establish that the drug is therapeutically equivalent to the innovator product

All ANDAs submitted pursuant to the PEPFAR program get a priority review

PEPFAR eligibility



Identified and validated by the Division of Filing Review



Meets Criteria






PEPFAR Information





PEPFAR Change Amendments



FDA


After Tentative Approval: FDA List



President's Emergency Plan for AIDS Relief (PEPFAR) Database

f share 🗴 tweet in linkedin 🧔 pin (t) 🛎 email 🖨 print

PEPFAR Applications to Date = 239 Number of Products = 303 **Single and Combination Products Populations for Use Application Status** 300 140 Co-Packaged 13-120 100 3-Fixed 200 80 Dose Single Combina 118 tion 60 60 40 100 20 ٥ Approved or Withdrawn Approved or Withdrawn Tentatively **ANDAs** Tentatively NDAs 2-Fixed Dose Approved Approved Combination 48 Adult and Pediatric Adult-Only ANDAS NDAs



PEPFAR Pearls

• Priority Review



- Contact the Regulatory Project Manager
- Patent Certification
- Package label other than English: must submit English translation to the Agency for review



Questions?



Tina T. Nhu Commander, U.S. Public Health Service Team Leader Regulatory Project Manager, Division of Project Management Office of Generic Drugs |CDER | U.S. FDA

Regulatory Best Practices for Global Access to Medicines, Including Anti-TB Medicines August 17, 2022